Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
BioConferenceLive

Programming Cells to Target Specific Tissues May Enable More Effective Cell-Based Therapies

By BiotechDaily International staff writers
Posted on 08 Nov 2011
Stem cell therapies hold huge potential to tackle some of the most devastating disorders, diseases, and tissue defects worldwide. However, the inability to target cells to tissues of interest poses a considerable hurdle to effective cell therapy. To address this obstacle, researchers have devised a platform approach to incorporate chemically homing receptors onto the surface of cells. This simple application has the potential to improve the effectiveness of many types of cell therapies by increasing the concentrations of cells at target locations in the body.

The study’s findings were published online in the journal Blood on October 27, 2011. For this new platform, researchers modified the surface of cells to include receptors that act as a homing device. “The central hypothesis of our work is that the ability of cells to home to specific tissues can be enhanced, without otherwise altering cell function,” said corresponding author Jeffrey M. Karp, PhD, codirector of the Regenerative Therapeutics Center at Brigham and Women’s Hospital (BWH; Boston, MA, USA), and a principal faculty member of the Harvard Stem Cell Institute. “By knowing the ‘zip code’ [US postal code] of the blood vessels in specific tissues, we can program the ‘address’ onto the surface of the cells to potentially target them with high efficiencies.”

Whereas traditional cell therapies that include local administration of cells can be useful, they are typically more invasive with limited potential for multiple doses. “You can imagine, that when the targeted tissue is cardiac muscle, for example to treat heart attacks or heart failure, injecting the cells directly into the heart can be an invasive procedure and typically this approach can only be performed once,” said Dr. Karp, also an assistant professor at Harvard Medical School (Boston, MA, USA) and affiliate faculty Harvard-Massachusetts Institute of Technology (MIT) Division of Health Sciences and Technology (Cambridge, MA, USA).

Using the platform the researchers created, the cells are prepared to travel directly to the area of interest after being injected through a common and much less invasive intravenous infusion technique. “These engineered cells may also be more effective because multiple doses can be administered,” stated Debanjan Sarkar, PhD, previously a postdoctoral fellow in Dr. Karp’s lab and now an assistant professor of Biomedical Engineering at the State University of New York, University at Buffalo (NY, USA).

“The necessity for a more effective delivery approach stems from the potential diseases cell therapy may address,” said Dr. Karp, noting that the approach can be used to systemically target bone producing cells to the bone marrow to treat osteoporosis, cardiomyocytes to the heart to treat ischemic tissue, neural stem cells to the brain to treat Parkinson’s disease, or endothelial progenitor cells to sites of peripheral vascular disease to promote formation of new blood vessels.

The researchers concluded that, as the determination of the processes of cell trafficking grows, the capability to improve homing to specific tissues through engineered techniques should considerably enhance cell therapy by reducing the invasiveness of local administration, allowing repeat dosing, and potentially reducing the number of cells needed to achieve a therapeutic effect, in the end providing better outcomes for patients.

Related Links:
Brigham and Women’s Hospital





comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel

Precise Ion Irradiation Dosing Method Developed for Cancer Therapy

Scientists are employing nuclear physics principles to provide more effective approaches to radiotherapy treatment for cancer patients. Radiation therapy using heavy ions is best suitable for cancer patients with tumors that are difficult to access, such as in the brain. These particles scarcely damage the penetrated... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.